A Study to Assess a PI3Kδ Inhibitor (IOA-244) in Patients With Metastatic Cancers
iOnctura
iOnctura
Massive Bio, Inc.
JaxBio Ltd
Celgene
Prelude Therapeutics
Asana BioSciences
Merck Sharp & Dohme LLC
Novartis
Cellerant Therapeutics
INSYS Therapeutics Inc